Dottikon ES Holding AG is a Swiss-based holding company specializing in the manufacture of high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for... Dottikon ES Holding AG is a Swiss-based holding company specializing in the manufacture of high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the global chemical, biotech, and pharmaceutical industries. Operating from its single production site in Dottikon, Aargau, Switzerland, the company excels in hazardous reactions, low-temperature chemistry, high-pressure processes, and continuous manufacturing, enabling safe scale-up from kilograms to multi-tons under cGMP conditions. With over 110 years of history dating back to 1913 as a specialist in explosives, Dottikon ES Holding AG has evolved into a performance leader, emphasizing a strong safety culture, process innovation, and sustainability to reduce energy use, waste, and CO2 emissions. Employing around 841 people, it serves diverse customers across Europe (73% of revenues), Switzerland (17%), the US (9%), and Asia (1%), with more than 80% of net sales from APIs. The firm's one-site strategy facilitates efficient project development, transparent documentation, and close client collaboration, positioning it as a trusted strategic partner in complex synthesis. Core technologies include azide chemistry, hydrogenations, oxidations, and advanced equipment for R&D, pilot, and production scales. Dottikon ES Holding AG underscores its role in advancing chemical manufacturing through expertise in highly exothermic, reactive, and unstable compounds.
Dottikon ES Holding is not subject to EU Taxonomy reporting
Based on current regulatory requirements, Dottikon ES Holding is not required to report EU
Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU
Taxonomy data review for this company.
If you believe this assessment should be revisited, you may submit a data coverage request
and our team will review the company's regulatory applicability.